Title: GSK Reports Strong Fourth-Quarter Sales and Raises Guidance for 2024

Global pharmaceutical company GSK has announced impressive fourth-quarter sales, driven by the success of its shingles vaccine. The company has also raised its guidance for 2024, indicating a positive outlook for the future.

Sales Topped £8 Billion:
GSK reported that its fourth-quarter sales exceeded £8 billion, a significant increase from the previous year. This growth can be attributed to the success of its shingles vaccine, which has become the company’s best-selling product.

Shingles Vaccine Driving Sales:
GSK’s shingles vaccine, Shingrix, has been a major contributor to the company’s strong sales performance. The vaccine has been in high demand, with sales reaching £1.7 billion in the fourth quarter alone. This success is expected to continue, as the vaccine has been approved in more than 90 countries and is currently being reviewed by regulatory authorities in China.

Raised Guidance for 2024:
In light of its strong sales performance, GSK has raised its guidance for 2024. The company now  

Share This Article
Leave a comment